|
Index of reports
> Cases resulting in a serious event (545)
> Cases with Pneumocystis Jiroveci Pneumonia (25)
Below is the selection of adverse event reports related to Rituxan (Rituximab) that includes cases resulting in a serious event where reactions include pneumocystis jiroveci pneumonia.
Reports 1 - 25 of 25 Next >>
Adverse event in 35 year old female receiving Rituxan (Rituximab)
Reported by a physician from United States on 2007-10-23
Patient: 35 year old female
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan (Rituximab)
Other drugs received by patient: Cyclophosphamide; Azathioprine; High Dose Steroids (Unk Ingredients)
Adverse event in female receiving Rituxan (Rituximab)
Reported by a physician from Japan on 2007-10-17
Patient: female, weighing 40.0 kg (88.0 pounds)
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Adverse event resulted in: death, life threatening event
Suspect drug(s):
Rituxan
Dosage: 470 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2004-09-08
End date: 2004-09-29
Rimatil
Dosage: 50 mg, unk
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2004-08-30
End date: 2004-10-12
Hydrocortisone Sodium Succinate
Dosage: 100 mg, unk
Indication: Drug USE FOR Unknown Indication
Start date: 2004-09-08
End date: 2004-09-27
Other drugs received by patient: Amlodipine Besylate; Bonalon; Pursennid; Urso 250; Steroid (Name Unknown); Lamivudine
Adverse event in female receiving Rituxan (Rituximab)
Reported by a physician from Japan on 2007-07-30
Patient: female
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan (Rituximab)
Other drugs received by patient: Adriamycin PFS; Cyclophosphamide; Oncovin; Predonine; Filgrastim
Adverse event in 30 year old receiving Rituxan (Rituximab)
Reported by a individual with unspecified qualification from Norway on 2007-07-24
Patient: 30 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Doxorubicin HCL
Dosage: daily dose:50mg/m*2
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: daily dose:100mg-freq:day1 to day5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: daily dose:750mg/m*2
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: daily dose:100mg/m*2-freq:day1 to day3
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Dosage: daily dose:1mg/m*2
Indication: non-Hodgkin's Lymphoma
Rituxan
Indication: non-Hodgkin's Lymphoma
Adverse event in 61 year old receiving Rituxan (Rituximab)
Reported by a individual with unspecified qualification from Norway on 2007-07-23
Patient: 61 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Doxorubicin HCL
Dosage: daily dose:50mg/m*2
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: daily dose:750mg/m*2
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: daily dose:100mg-freq:day1 to day5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: daily dose:100mg/m*2-freq:day1 to day3
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Dosage: daily dose:1mg/m*2
Indication: non-Hodgkin's Lymphoma
Rituxan
Adverse event in 49 year old receiving Rituxan (Rituximab)
Reported by a individual with unspecified qualification from Norway on 2007-07-23
Patient: 49 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Indication: non-Hodgkin's Lymphoma
Prednisolone
Indication: non-Hodgkin's Lymphoma
Etoposide
Indication: non-Hodgkin's Lymphoma
Rituxan
Indication: non-Hodgkin's Lymphoma
Adverse event in 47 year old receiving Rituxan (Rituximab)
Reported by a individual with unspecified qualification from Norway on 2007-07-23
Patient: 47 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Doxorubicin HCL
Dosage: daily dose:50mg/m*2
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: daily dose:100mg-freq:day1 to day5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: daily dose:750mg/m*2
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: daily dose:100mg/m*2-freq:day1 to day3
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Dosage: daily dose:1mg/m*2
Indication: non-Hodgkin's Lymphoma
Rituxan
Indication: non-Hodgkin's Lymphoma
Adverse event in 47 year old receiving Rituxan (Rituximab)
Reported by a individual with unspecified qualification from Norway on 2007-07-23
Patient: 47 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Etoposide
Indication: non-Hodgkin's Lymphoma
Prednisolone
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituxan
Adverse event in 58 year old receiving Rituxan (Rituximab)
Reported by a individual with unspecified qualification from Norway on 2007-07-23
Patient: 58 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Doxorubicin HCL
Dosage: daily dose:50mg/m*2
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: daily dose:100mg-freq:day1 to day5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: daily dose:750mg/m*2
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: daily dose:100mg/m*2-freq:day1 to day3
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Dosage: daily dose:1mg/m*2
Indication: non-Hodgkin's Lymphoma
Rituxan
Indication: non-Hodgkin's Lymphoma
Adverse event in 38 year old female receiving Rituxan (Rituximab)
Reported by a physician from Japan on 2007-07-19
Patient: 38 year old female
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan (Rituximab)
Other drugs received by patient: Adriamycin PFS; Endoxan; Oncovin; Predonine; Filgrastim
Adverse event in 53 year old female receiving Rituxan (Rituximab)
Reported by a health professional (non-physician/pharmacist) from Japan on 2007-07-18
Patient: 53 year old female
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan (Rituximab)
Other drugs received by patient: Adriamycin PFS; Endoxan; Oncovin; Predonine
Adverse event in 37 year old male receiving Rituxan (Rituximab)
Reported by a physician from United States on 2007-04-19
Patient: 37 year old male
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Adverse event resulted in: death
Suspect drug(s):
Rituxan (Rituximab)
Other drugs received by patient: Prednisone TAB; Prednisone TAB; Cyclophosphamide
Adverse event in receiving Rituxan (Rituximab)
Reported by a physician from Norway on 2007-03-22
Patient:
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Opportunistic Infection
Suspect drug(s):
Mabthera (Rituximab) Conc FOR Solution FOR Infusion
Dosage: q3w
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, q3w, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, q3w, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, q3w, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, q32, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituxan
Dosage: q3w
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, q3w, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, q3w, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, q3w, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, q32, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in receiving Rituxan (Rituximab)
Reported by a physician from Norway on 2007-03-22
Patient:
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Opportunistic Infection
Suspect drug(s):
Mabthera (Rituximab) Conc FOR Solution FOR Infusion
Dosage: q14d
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, q14d, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituxan
Dosage: q14d
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, q14d, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in receiving Rituxan (Rituximab)
Reported by a physician from Norway on 2007-03-22
Patient:
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Opportunistic Infection
Suspect drug(s):
Mabthera (Rituximab) Conc FOR Solution FOR Infusion
Dosage: q14d
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, q14d, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituxan
Dosage: q14d
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, q14d, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, q14d, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 58 year old receiving Rituxan (Rituximab)
Reported by a physician from Norway on 2007-03-21
Patient: 58 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: 100 mg/m2, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 30 year old receiving Rituxan (Rituximab)
Reported by a health professional (non-physician/pharmacist) from Norway on 2007-03-20
Patient: 30 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan
Dosage: intravenous
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: 100 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: 100 mg/m2, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 61 year old receiving Rituxan (Rituximab)
Reported by a health professional (non-physician/pharmacist) from Norway on 2007-03-20
Patient: 61 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan
Dosage: intravenous
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: 100 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: 100 mg, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 49 year old receiving Rituxan (Rituximab)
Reported by a physician from Norway on 2007-03-20
Patient: 49 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan
Indication: non-Hodgkin's Lymphoma
Cyclophasphamide(cyclophosphamide)
Dosage: 750 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: 100 mg/m2 intravenous
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: 100 mg, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 47 year old receiving Rituxan (Rituximab)
Reported by a health professional (non-physician/pharmacist) from Norway on 2007-03-20
Patient: 47 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Rituxan
Dosage: intravenous
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: 100 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: 100 mg, oral
Administration route: Oral
Adverse event in 47 year old receiving Rituxan (Rituximab)
Reported by a physician from Norway on 2007-03-20
Patient: 47 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Opportunistic Infection
Suspect drug(s):
Rituxan
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 1.4 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Etoposide
Dosage: 100 mg/m2, intravenous
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 100 mg, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 64 year old male receiving Rituxan (Rituximab)
Reported by a physician from Japan on 2007-03-08
Patient: 64 year old male
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Adverse event resulted in: hospitalization
Suspect drug(s):
Rituxan
Dosage: 640 mg, qd intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2006-05-10
Adriamycin PFS
Dosage: 86 mg intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2006-05-12
Cyclophosphamide
Dosage: 1250 mg intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2006-05-12
Oncovin
Dosage: 2 mg intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2006-05-12
Prednisolone
Dosage: 500 mg oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Start date: 2006-05-12
Other drugs received by patient: Methylcobalamin (Cyanocobalamin); Hytril (Granisetron Hydrochloride); Lafutidine (Lafutidine)
Adverse event in 47 year old receiving Rituxan (Rituximab)
Reported by a health professional (non-physician/pharmacist) from Norway on 2007-03-08
Patient: 47 year old
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia
Suspect drug(s):
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Etoposide
Indication: non-Hodgkin's Lymphoma
Vincristine Sulfate
Indication: non-Hodgkin's Lymphoma
Rituxan
Indication: non-Hodgkin's Lymphoma
Prednisolone
Indication: non-Hodgkin's Lymphoma
Adverse event in receiving Rituxan (Rituximab)
Reported by a physician from Japan on 2007-01-25
Patient:
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Interstitial Lung Disease
Adverse event resulted in: hospitalization
Suspect drug(s):
Rituxan
Dosage: intravenous
Indication: Lymphoma
Adriamycin PFS
Dosage: intravenous
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: intravenous
Indication: non-Hodgkin's Lymphoma
Oncovin
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Adverse event in 68 year old male receiving Rituxan (Rituximab)
Reported by a pharmacist from United States on 2007-01-11
Patient: 68 year old male
Adverse reactions / side effects: Respiratory Disorder, Tachycardia, Pneumocystis Jiroveci Infection, Anaemia, Condition Aggravated, Computerised Tomogram Abnormal, Pneumocystis Jiroveci Pneumonia, Lung Disorder, Interstitial Lung Disease, Chest Pain, Diffuse Alveolar Damage, Pneumonitis, Immunosuppression
Adverse event resulted in: hospitalization
Suspect drug(s):
Rituxan (Rituximab)
Page 1 Next >>
|
